Survivorship of Attune Primary Total Knee Prosthesis

Sponsor
DePuy International (Industry)
Overall Status
Active, not recruiting
CT.gov ID
NCT01754363
Collaborator
(none)
1,542
36
1
204
42.8
0.2

Study Details

Study Description

Brief Summary

This post-marketing investigation will evaluate the long term (up to 15 years) survivorship of the Attune Primary Knee Prosthesis in patients with non-inflammatory degenerative joint disease. Data from Subjects who receive one of four knee configurations will be pooled to establish a contemporary dataset.

Condition or Disease Intervention/Treatment Phase
  • Device: Attune Primary Total Knee Replacement
N/A

Detailed Description

Approximately 30 sites, worldwide, will recruit 1200 patients (1200 knees). Each study site is expected to enroll approximately 50 patients (50 knees). An additional 10 subjects per site may be recruited at sites which have Sub-Investigators participating in the study. Cohort reallocation is permitted. There is no control group. One thousand two hundred (1200) Subjects will be stratified into 4 subgroups of 300: cruciate retaining fixed bearing(CR FB), cruciate retaining rotating platform (CR RP), posterior stabilized fixed bearing (PS FB), and posterior stabilized rotating platform (PS RP).

Treatment assignment in this study is not randomized. Each site will only enroll patients in one of the four knee configuration sub-groups most commonly used as their standard of care.

This study allowed for enrolment into the study by two methods. The first method was by enroling subjects to receive the implant under study with the expectation to follow them out to 15 years. The second method was done to offset follow-up attrition. The second method allowed additional interested sites that had previously participated in a two-year follow-up study (NCT01746524) on this implant (subjects implanted and followed for two years) to reconsent interested subjects to be further followed out to 15 years in this study. The original 29 sites enroled 1232 subjects. Adding of the interested sites from the 2-yr follow-up study (NCT01746524) increased the sites from 29 to 37 sites. As of the last study update, the current enrolment is now1538.

Study Design

Study Type:
Interventional
Actual Enrollment :
1542 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Short, Medium and Long Term Survivorship of Attune Primary Knee Prosthesis
Actual Study Start Date :
Feb 1, 2013
Anticipated Primary Completion Date :
Feb 1, 2030
Anticipated Study Completion Date :
Feb 1, 2030

Arms and Interventions

Arm Intervention/Treatment
Experimental: Attune Primary Total Knee Replacement

Subjects will receive one of the following Attune total knee implants: Cruciate retaining fixed bearing (CR FB) Cruciate retaining rotating platform (CR RP) Posterior stabilized fixed bearing (PS FB) Posterior stabilized rotating platform (PS RP)

Device: Attune Primary Total Knee Replacement
Patients will undergo a primary total knee replacement using one of the four configurations of the Attune knee (CR FB, CR RP, PS FB, PS RP).

Outcome Measures

Primary Outcome Measures

  1. Survivorship of each configuration. [Minimum 15 years (5414 - 5658 days)]

    Kaplan-Meier survival analysis will be used to calculate the survivorship of all 4 configurations (CR FB, CR RP, PS FB, PS RP).

Secondary Outcome Measures

  1. Survivorship [Minimum 5 years (1764 - 3588 days)]

    Kaplan-Meier survival analysis will be used to calculate the survivorship of all 4 configurations (CR FB, CR RP, PS FB, PS RP).

  2. Survivorship [Minimum 10 years (3589 - 5413 days)]

    Kaplan-Meier survival analysis will be used to calculate the survivorship of all 4 configurations (CR FB, CR RP, PS FB, PS RP).

  3. Implant fixation: Radiographic assessment of bone-implant interface performance [Minimum 1 year (304 - 668 days)]

    Radiographic success is defined as: absence of progressive radiolucent lines greater than or equal to 2mm in any one zone; absence of lytic lesions in any zone; absence of individual component position change >3degrees in any plane.

  4. Implant fixation: Radiographic assessment of bone-implant interface performance [Minimum 2 years (669 - 1763 days)]

    Radiographic success is defined as: absence of progressive radiolucent lines greater than or equal to 2mm in any one zone; absence of lytic lesions in any zone; absence of individual component position change >3degrees in any plane.

  5. Implant fixation: Radiographic assessment of bone-implant interface performance [Minimum 5 years (1764 - 3588 days)]

    Radiographic success is defined as: absence of progressive radiolucent lines greater than or equal to 2mm in any one zone; absence of lytic lesions in any zone; absence of individual component position change >3degrees in any plane.

  6. Implant fixation: Radiographic assessment of bone-implant interface performance [Minimum 10 years (3589 - 5413 days)]

    Radiographic success is defined as: absence of progressive radiolucent lines greater than or equal to 2mm in any one zone; absence of lytic lesions in any zone; absence of individual component position change >3degrees in any plane.

  7. Implant fixation: Radiographic assessment of bone-implant interface performance [Minimum 15 years (5414 - 5658 days)]

    Radiographic success is defined as: absence of progressive radiolucent lines greater than or equal to 2mm in any one zone; absence of lytic lesions in any zone; absence of individual component position change >3degrees in any plane.

  8. Patient Reported Outcome: EuroQol 5D 3L questionnaire (EQ-5D-3L) [Pre-op (-90 to -1 days before surgery), <1 year (1 - 303 days), minimum 1 year (304 - 668 days), minimum 2 years (669 - 1763 days), minimum 5 years (1764 - 3588 days), minimum 10 years (3589 - 5413 days), minimum 15 years (5414 - 5658 days).]

    EuroQol 5D 3L questionnaire is a standardized instrument for use as a measure of health outcome that is designed for completion by the subject.

  9. Patient-reported Outcome: Oxford Knee Score [Pre-op (-90 to -1 days before surgery), <1 year (1 - 303 days), minimum 1 year (304 - 668 days), minimum 2 years (669 - 1763 days), minimum 5 years (1764 - 3588 days), minimum 10 years (3589 - 5413 days), minimum 15 years (5414 - 5658 days).]

    The Oxford Knee Score (OKS) is a patient self-administered 12-item questionnaire with each question having a Likert-lie response option. Each item is scored from 0 to 4, and the items are summated, with lower total scores indicating poorer performance. The OKS measures pain and general activities of daily living.

  10. Patient-reported Outcome: Knee Injury and Osteoarthritis Outcome Score (KOOS) [Pre-op (-90 to -1 days before surgery), <1 year (1 - 303 days), minimum 1 year (304 - 668 days), minimum 2 years (669 - 1763 days), minimum 5 years (1764 - 3588 days), minimum 10 years (3589 - 5413 days), minimum 15 years (5414 - 5658 days).]

    The Knee injury and Osteoarthritis Outcome Score (KOOS) is a patient self-administered questionnaire that consists of 42 questions and includes the WOMAC Osteoarthritis index. The KOOS consists of 5 subscales; pain, other symptoms, activities of daily living (ADL), sport and recreational function and knee related quality of life. Each question has 5 Likert- like response options. A normalized score (100 indicating no symptoms and 0 indicating extreme symptoms) is calculated for each subscale.

  11. Patient-reported Outcome: Pre-surgical/Post-surgical Patient's Knee Implant Performance (PKIP) [Pre-op (-90 to -1 days before surgery), <1 year (1 - 303 days), minimum 1 year (304 - 668 days), minimum 2 years (669 - 1763 days), minimum 5 years (1764 - 3588 days), minimum 10 years (3589 - 5413 days), minimum 15 years (5414 - 5658 days).]

    The Pre Surgical and/or Post-surgical Patient's Knee Implant Performance (PKIP) questionnaire is a patient self-administered questionnaire that consists of 25 questions relating to the patient's awareness of their knee. Questions include the patient's self-confidence about the current status of their knee performance, stability, and overall satisfaction. Each question has a 5, 6 or 10 Likert- like response option.

  12. Patient-reported Outcome: Knee Society Score [Pre-op (-90 to -1 days before surgery), <1 year (1 - 303 days), minimum 1 year (304 - 668 days), minimum 2 years (669 - 1763 days), minimum 5 years (1764 - 3588 days), minimum 10 years (3589 - 5413 days), minimum 15 years (5414 - 5658 days).]

    The Knee Society Score is a self-administered questionnaire. The subject completes questions regarding: Symptoms (3 questions), Patient Satisfaction (5 questions), Patient Expectations (3 questions), Functional Activities (5 questions), Standard Activities (6 questions), Advanced Activities (5 questions), and Discretionary Knee Activities ( 4 questions). Likert responses are used, typically with five response options.

  13. Evaluate the impact of surgeon learning curve on clinical and functional outcomes [<1 year (1 - 303 days), minimum 1 year (304 - 668 days), minimum 2 years (669 - 1763 days), minimum 5 years (1764 - 3588 days), minimum 10 years (3589 - 5413 days), minimum 15 years (5414 - 5658 days).]

    A surgeon learning curve will be investigated by comparing learning curve cases (the pooled cohort of each surgeon's first 10 study Subjects) with all investigational Subjects. All primary and secondary outcomes will be compared across the learning curve and post-learning curve Subject cohorts.

  14. Evaluate changes in femoral component and tibial component alignment [Pre-op (-90 to -1 days before surgery), <1 year (1 - 303 days), minimum 1 year (304 - 668 days), minimum 2 years (669 - 1763 days), minimum 5 years (1764 - 3588 days), minimum 10 years (3589 - 5413 days), minimum 15 years (5414 - 5658 days).]

    Radiographs will be reviewed by an independent radiographic reviewer (IRR) in order to minimize bias of radiographic outcomes. Data from the IRR radiographic evaluations will be used to evaluate femoral and tibial component alignment over time.

  15. Type and Frequency of Adverse Events (AEs) for all enrolled subjects [Pre-op (-90 to -1 days before surgery), <1 year (1 - 303 days), minimum 1 year (304 - 668 days), minimum 2 years (669 - 1763 days), minimum 5 years (1764 - 3588 days), minimum 10 years (3589 - 5413 days), minimum 15 years (5414 - 5658 days).]

    All Serious AEs must be reported to Sponsor. All device-related or procedure-related adverse events must be reported to Sponsor.

Eligibility Criteria

Criteria

Ages Eligible for Study:
22 Years to 75 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Subject is male or female and between the ages of 22 and 75 years at the time of surgery, inclusive.

  • Subject was diagnosed with NIDJD.

  • Subject is a suitable candidate for cemented primary total knee arthroplasty using the devices described in this protocol with either resurfaced or non-resurfaced patellae.

  • Subject has given voluntary, written informed consent to participate in this clinical investigation and has authorized the transfer of his/her information to DePuy.

  • Subject is currently not bedridden.

  • Subject in the opinion of the Clinical Investigator, is able to understand this clinical investigation and is willing and able to perform all study procedure and follow-up visits and co-operate with investigational procedures.

  • Subject must be comfortable with speaking, reading and understanding questions and providing responses in an available translated language for the PROs in the protocol.

  • The devices specified in this protocol were implanted.

Exclusion Criteria:
  • Subject is a woman who is pregnant or lactating.

  • Contralateral knee has already been enrolled in this study.

  • Subject had a contralateral amputation.

  • Previous partial knee replacement (unilateral, bicompartmental or patellofemoral joint replacement), patellectomy, high tibial osteotomy or primary TKA in affected knee.

  • Subject is currently experiencing radicular pain from the spine.

  • Subject has participated in an IDE/IND clinical investigation with an investigational product in the last three months.

  • Subject is currently involved in any personal injury litigation, medical-legal or worker's compensation claims.

  • Subject is a known drug or alcohol abuser or has a psychological disorder that could affect their ability to complete patient reported questionnaires.

  • Subject was diagnosed with fibromyalgia that is currently being treated with prescription medication.

  • Subject has significant neurological or musculoskeletal disorders or disease that may adversely affect gait or weight bearing (e.g. muscular dystrophy, multiple sclerosis, Charcot disease).

  • Subject is suffering from inflammatory arthritis (e.g. rheumatoid arthritis, juvenile rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosis, etc.).

  • Subject is not comfortable with speaking, reading, and understanding questions and providing responses in an available translated language for the PROs in the protocol.

  • Subject has a medical condition with less than 5 years of life expectancy.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Mayo Clinic Arizona Scottsdale Arizona United States 85259
2 Orthopaedic Specialty Institute Orange California United States 92868
3 Orthopaedic Center of the Rockies Fort Collins Colorado United States 80525
4 Florida Research Associates, LLC DeLand Florida United States 32720
5 Center for Hip and Knee Surgery Mooresville Indiana United States 46158
6 Miller Orthopedic Specialists Council Bluffs Iowa United States 51503
7 University of Iowa Hospitals & Clinics Iowa City Iowa United States 52242
8 The Arthroplasty Foundation, Inc. Louisville Kentucky United States 40215
9 Anne Arundel Orthopaedic Surgeons Annapolis Maryland United States 21401
10 Washington University School of Medicine Saint Louis Missouri United States 63110
11 New London Hospital New London New Hampshire United States 03257
12 Cardinal Orthopaedic Institute Columbus Ohio United States 43213
13 OrthoNeuro Westerville Ohio United States 43081
14 Penn State Hershey Bone & Joint Institute Hershey Pennsylvania United States 17033
15 Abington Orthopaedic Specialists, PC Willow Grove Pennsylvania United States 19090
16 Texas Institute for Hip and Knee Surgery, LLC Austin Texas United States 78705
17 Canberra Hospital-Trauma & Orthopaedic Research Unit Adelaide South Australia Australia ACT 2600
18 Univ.-Klinik für Orthopädie Vienna Lower Austria Austria 1090
19 Krankenhaus der Barmherzigen Linz Upper Austria Austria 4010
20 Monica Camputs O.L.V. Middelares Antwerp Belgium 2100
21 University of Western Ontario-Department of Orthopaedic Surgery London Ontario Canada N6A 5A5
22 Orthopädische Klinik für die Universität Regensburg Bad Abbach Bavaria Germany 3077
23 UniversitatsKlinikum Heidelberg Heidelberg Germany 69118
24 Queen Mary Hospital Pokfulam Hong Kong
25 Seoul National Univ Bundang Hospital - Joint Reconstruction Center Seoul Gyeonggi-do Korea, Republic of 463-707
26 Seoul National University Hospital Seoul Korea, Republic of 110-744
27 University Malaya Medical Centre Kuala Lumpur Malaysia 59100
28 Ascot Hospital Auckland New Zealand
29 Singapore General Hospital-Dept of Orthopaedic Surgery Singapore Singapore 169608
30 Schulthess Klinik Zurich Switzerland
31 Bhumibol Adulyadej Hospital, The Royal Thai Air Force-Dept of Orthopaedics Bangkok Thailand 10220
32 Queen Mary Hospital Dunfermline Fife United Kingdom KY12 OSU
33 New Royal Infirmary of Edinburgh Edinburgh Scotland United Kingdom EH16 4SA
34 Princess Alexandria Hospital Harlow United Kingdom CM20 1QX
35 Guys Hospital London United Kingdom SE1 9RT
36 Clifton Park NHS Treatment Centre York United Kingdom YO30 5RA

Sponsors and Collaborators

  • DePuy International

Investigators

  • Study Director: Kirstin Cosgrove, DePuy Synthes

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
DePuy International
ClinicalTrials.gov Identifier:
NCT01754363
Other Study ID Numbers:
  • 10008
First Posted:
Dec 21, 2012
Last Update Posted:
Aug 9, 2022
Last Verified:
Aug 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
No
Keywords provided by DePuy International
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 9, 2022